HK1208377A1 - Lipid-based drug carriers for rapid penetration through mucus linings - Google Patents

Lipid-based drug carriers for rapid penetration through mucus linings

Info

Publication number
HK1208377A1
HK1208377A1 HK15109178.8A HK15109178A HK1208377A1 HK 1208377 A1 HK1208377 A1 HK 1208377A1 HK 15109178 A HK15109178 A HK 15109178A HK 1208377 A1 HK1208377 A1 HK 1208377A1
Authority
HK
Hong Kong
Prior art keywords
lipid
based drug
drug carriers
rapid penetration
mucus linings
Prior art date
Application number
HK15109178.8A
Other languages
English (en)
Chinese (zh)
Inventor
Justin Hanes
Kannie Wai Yan Chan
Michael T Mcmahon
Ming Yang
Tao Yu
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of HK1208377A1 publication Critical patent/HK1208377A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15109178.8A 2012-05-04 2015-09-18 Lipid-based drug carriers for rapid penetration through mucus linings HK1208377A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642776P 2012-05-04 2012-05-04
PCT/US2013/039731 WO2013166498A1 (fr) 2012-05-04 2013-05-06 Véhicules de médicament à base de lipide pour pénétration rapide à travers les revêtements de mucus

Publications (1)

Publication Number Publication Date
HK1208377A1 true HK1208377A1 (en) 2016-03-04

Family

ID=48428718

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109178.8A HK1208377A1 (en) 2012-05-04 2015-09-18 Lipid-based drug carriers for rapid penetration through mucus linings

Country Status (7)

Country Link
US (2) US9889208B2 (fr)
EP (1) EP2849728A1 (fr)
JP (2) JP6392209B2 (fr)
AU (1) AU2013256008B2 (fr)
CA (1) CA2872519C (fr)
HK (1) HK1208377A1 (fr)
WO (1) WO2013166498A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713514B1 (fr) * 2004-01-28 2021-11-24 Johns Hopkins University Medicaments et particules de transport de genes se depla ant rapidement a travers les barrieres muqueuses
WO2011106702A2 (fr) 2010-02-25 2011-09-01 The Johns Hopkins University Délivrance prolongée d'agents thérapeutiques à un compartiment oculaire
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012039979A2 (fr) 2010-09-10 2012-03-29 The Johns Hopkins University Diffusion rapide de grosses nanoparticules polymères dans le cerveau de mammifères
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
WO2012109363A2 (fr) 2011-02-08 2012-08-16 The Johns Hopkins University Vecteurs géniques pénétrant le mucus
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
CN104394891B (zh) 2012-03-16 2019-04-16 约翰霍普金斯大学 用于递送活性剂的非线性多嵌段共聚物-药物结合物
CA2867381C (fr) 2012-03-16 2016-09-20 The Johns Hopkins University Formulations a liberation controlee pour l'administration d'inhibiteurs du hif-1
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
EP3808339A1 (fr) 2012-05-03 2021-04-21 Kala Pharmaceuticals, Inc. Nanoparticles pharmaceutiques montrant du transport mucosale amélioré
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9889208B2 (en) * 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
EP4074834A1 (fr) 2012-11-26 2022-10-19 ModernaTX, Inc. Arn à terminaison modifiée
WO2014124006A1 (fr) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticules pour le suivi de l'imagerie par résonance magnétique et procédés de fabrication et d'utilisation associés
EP2971010B1 (fr) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
US10335500B2 (en) 2014-05-12 2019-07-02 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
CN107278151A (zh) 2014-12-15 2017-10-20 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
US20180139997A1 (en) * 2015-06-15 2018-05-24 Gexnano S.R.L. Food supplement for use in a process of metabolic rebalancing
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés pour le traitement de troubles immunitaires et inflammatoires
SI3350157T1 (sl) 2015-09-17 2022-04-29 Modernatx, Inc. Sestave za doziranje terapevtskih sredstev v celice
JP2018536017A (ja) 2015-09-22 2018-12-06 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための化合物及び組成物
CA3003733C (fr) * 2015-10-30 2021-04-20 The Johns Hopkins University Particules a poids moleculaire eleve penetrant dans le mucus et revetements denses
WO2017083779A1 (fr) 2015-11-12 2017-05-18 Graybug Vision, Inc. Aggrégation de microparticules pour un usage thérapeutique
US10905783B2 (en) * 2015-11-27 2021-02-02 Michal RIVLIN Glucosamine and derivatives thereof in imaging
EP3964200A1 (fr) 2015-12-10 2022-03-09 ModernaTX, Inc. Compositions et procédés permettant d'administrer des agents thérapeutiques
JP7114465B2 (ja) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド 薬剤の細胞内送達のための化合物および組成物
US10901058B2 (en) * 2016-02-05 2021-01-26 The Trustees Of The University Of Pennsylvania Chemical exchange saturation transfer (CEST) imaging of lactate (LATEST)
US11938200B2 (en) 2016-02-05 2024-03-26 The Trustees Of The University Of Pennsylvania Non-nutritive sweeteners and polyols as imaging agents
CA3015639A1 (fr) * 2016-03-09 2017-09-14 Technion Research And Development Foundation Ltd. Formulations liposomales et leurs procedes d'utilisation en agriculture
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
US10842746B1 (en) * 2016-08-25 2020-11-24 Verily Life Sciences Llc Bi-directionally crosslinked liposomes and method of making same
WO2018089540A1 (fr) 2016-11-08 2018-05-17 Modernatx, Inc. Formulations stabilisées de nanoparticules lipidiques
DK3596041T3 (da) 2017-03-15 2023-01-23 Modernatx Inc Forbindelse og sammensætninger til intracellulær afgivelse af terapeutiske midler
ES2911186T3 (es) 2017-03-15 2022-05-18 Modernatx Inc Formas cristalinas de aminolípidos
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
EP3600324A4 (fr) 2017-03-23 2020-12-09 Graybug Vision, Inc. Composés et compositions pour le traitement de troubles oculaires
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
US20210069121A1 (en) 2017-12-12 2021-03-11 Lead Biotherapeutics Ltd Solid lipid nanoparticle for intracellular release of active substances and method for production the same
EP3841086A4 (fr) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
US20220054455A1 (en) * 2018-09-13 2022-02-24 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
EP3866773A4 (fr) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Promédicaments de monoxyde de carbone pour le traitement de troubles médicaux
MX2022003269A (es) 2019-09-19 2022-07-04 Modernatx Inc Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos.
JP7485584B2 (ja) 2020-11-02 2024-05-16 矢崎総業株式会社 熱収縮チューブ装着用治具
US11058637B1 (en) * 2020-11-25 2021-07-13 King Abdulaziz University Surface-modified emulsomes for intranasal delivery of drugs
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022185993A1 (fr) 2021-03-02 2022-09-09 新明和工業株式会社 Dispositif de chauffage de tube thermorétractable
CA3217928A1 (fr) * 2021-05-05 2022-11-10 Kameswari S. Konduri Inhibition de la replication du sars-cov-2 et reduction de l'inflammation pulmonaire par corticosteriods encapsules dans des liposomes

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2026989A (en) 1931-08-12 1936-01-07 T R C Corp Method of building roads
US2005204A (en) 1933-02-23 1935-06-18 Ralph R Poynter Lawn mower
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5196522A (en) 1990-11-01 1993-03-23 Board Of Regents, The University Of Texas System Anthracycline analogues bearing latent alkylating substituents
US5696298A (en) 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
KR100266912B1 (ko) 1992-02-28 2000-12-01 파라비 레이 조직접촉물질이며 방출조절운반체인 광중합성 생분해성 하이드로겔
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
ES2227536T3 (es) 1995-06-27 2005-04-01 Pharmachemie B.V. Nuevos profarmacos de antraciclina, procedimiento de preparacion asi como su uso en quimioterapia selectiva.
DE69729646T2 (de) 1996-05-09 2005-07-07 Infectio Recherce Inc., Ste-Foy Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv
US5869130A (en) 1997-06-12 1999-02-09 Mac Dermid, Incorporated Process for improving the adhesion of polymeric materials to metal surfaces
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
WO2000066180A2 (fr) 1999-04-21 2000-11-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Procede pour ameliorer le contraste d'une image obtenue par irm
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6413639B1 (en) 1999-10-01 2002-07-02 Toda Kogyo Corporation Mg-Al based hydrotalcite-type particles, chlorine-containing resin stabilizer and process for producing the particles
CA2393595A1 (fr) * 1999-12-10 2001-06-14 Gigi Chiu Compositions d'excipient a base de lipides ayant des fonctions de reaction au moyen d'une surface protegee
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP2316490A3 (fr) 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Methodes et compositions pour améliorer l'administration de molécules bioactives
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7381426B2 (en) * 2002-01-24 2008-06-03 Southwest Research Institute Targeted delivery of bioactive factors to the systemic skeleton
US7901708B2 (en) * 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
MXPA05007146A (es) 2002-12-30 2005-09-21 Nektar Therapeutics Al Corp Copolimeros en bloque de polipeptido-poli(etilenglicol) de ramificaciones multiples como vehiculos para suministro de farmacos.
US20050009910A1 (en) 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
KR20070019941A (ko) * 2003-09-03 2007-02-16 교와 핫꼬 고교 가부시끼가이샤 글리세롤 유도체로 수식된 화합물
GB0328630D0 (en) 2003-12-10 2004-01-14 Medpharm Ltd Metered dose inhalation preparations
CA2548376A1 (fr) 2003-12-31 2005-07-21 Pfizer Products Inc. Compositions solides a base de medicaments peu solubles et de poloxameres
EP1713514B1 (fr) 2004-01-28 2021-11-24 Johns Hopkins University Medicaments et particules de transport de genes se depla ant rapidement a travers les barrieres muqueuses
WO2005076998A2 (fr) 2004-02-05 2005-08-25 Intradigm Corporation Therapeutique par des agents rnai appliquee dans le traitement de maladies oculaires resultant d'une neovascularisation
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8354476B2 (en) 2004-12-10 2013-01-15 Kala Pharmaceuticals, Inc. Functionalized poly(ether-anhydride) block copolymers
EP1871424A2 (fr) 2005-04-22 2008-01-02 Alza Corporation Composition d'immunoliposomes destinee au ciblage d'un recepteur des cellules her2
JP2006335745A (ja) * 2005-06-06 2006-12-14 Fujifilm Holdings Corp リポソームを含むｍｒｉ造影剤
WO2007016380A2 (fr) 2005-07-28 2007-02-08 (Osi) Eyetech, Inc. Dispositifs et methodes d'execution de procedures sur un sein
US20070071756A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
US20070093461A1 (en) 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
JP2009521493A (ja) 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
US8663674B2 (en) 2006-01-13 2014-03-04 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20070231360A1 (en) 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
US20070249536A1 (en) 2006-04-25 2007-10-25 Ma Peter X Three-component polyanhydride copolymers and a method of forming the same
US8858989B2 (en) * 2006-05-18 2014-10-14 Biolitec Pharma Marketing Ltd Gel-formulations of hydrophobic photosensitizers for mucosal applications
JP2008053276A (ja) 2006-08-22 2008-03-06 Nec Electronics Corp 半導体装置の製造方法
CA2663003C (fr) 2006-09-08 2018-02-13 Justin Hanes Compositions et methodes destinees a ameliorer le transport a travers le mucus
US8394488B2 (en) 2006-10-06 2013-03-12 Cordis Corporation Bioabsorbable device having composite structure for accelerating degradation
KR20140032505A (ko) 2006-11-09 2014-03-14 알콘 리서치, 리미티드 약물 전달용 수불용성 폴리머 매트릭스
WO2008109031A2 (fr) * 2007-03-02 2008-09-12 Luna Innovations Incorporated Transporteurs de type liposome pour la distribution in vivo de fullerènes
JP5640207B2 (ja) 2007-10-08 2014-12-17 セラオプティクスＴｈｅｒａｏｐｔｉｃｓ 水性眼用処方物
JP2009096749A (ja) * 2007-10-16 2009-05-07 Konica Minolta Holdings Inc コレステロール誘導体、リポソーム及びｘ線用造影剤
WO2009100176A2 (fr) 2008-02-07 2009-08-13 Abbott Laboratories Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase
US20100063135A1 (en) * 2008-09-10 2010-03-11 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
CN102245214B (zh) 2008-10-10 2014-10-29 波利艾克蒂瓦有限公司 生物可降解聚合物-生物活性部分缀合物
US20120052041A1 (en) 2009-02-04 2012-03-01 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
BRPI1012302A2 (pt) 2009-03-03 2015-09-22 Alcon Res Ltd composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
EP2440181A2 (fr) * 2009-06-08 2012-04-18 Epitarget AS Particules d'administration de medicament acoustiquement sensibles comprenant de la phosphatidylethanolamine
EP2335686A1 (fr) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. Nanosuspension intraveineuse aqueuse dotée d'effets indésirables diminués
WO2011106702A2 (fr) 2010-02-25 2011-09-01 The Johns Hopkins University Délivrance prolongée d'agents thérapeutiques à un compartiment oculaire
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
WO2011133803A1 (fr) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions et méthodes d'inactivation ciblée de récepteurs de surface cellulaire de vih
EP2407157A1 (fr) * 2010-07-13 2012-01-18 Koninklijke Philips Electronics N.V. Transporteur de lipides bicouche pour médicaments ou agents d'imagerie
WO2012039979A2 (fr) 2010-09-10 2012-03-29 The Johns Hopkins University Diffusion rapide de grosses nanoparticules polymères dans le cerveau de mammifères
WO2012061703A1 (fr) 2010-11-05 2012-05-10 The Johns Hopkins University Compositions et procédés visant à une réduction de la mucoadhérence
WO2012109363A2 (fr) 2011-02-08 2012-08-16 The Johns Hopkins University Vecteurs géniques pénétrant le mucus
CN102379850B (zh) * 2011-11-04 2013-08-28 北京泰德制药股份有限公司 一种穿越人体粘液屏障的靶向给药脂质体
EP2790733B1 (fr) 2011-12-14 2019-10-30 The Johns Hopkins University Nanoparticules présentant une pénétration mucosale accrue ou une inflammation diminuée
US20130217657A1 (en) 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
KR101811917B1 (ko) 2012-01-19 2017-12-22 더 존스 홉킨스 유니버시티 점액 침투 강화를 나타내는 나노 입자 제형
EP2819652A1 (fr) * 2012-02-27 2015-01-07 Epitarget As Utilisation d'un immunomodulateur particulaire en cancérothérapie
CA2867381C (fr) 2012-03-16 2016-09-20 The Johns Hopkins University Formulations a liberation controlee pour l'administration d'inhibiteurs du hif-1
CN104394891B (zh) 2012-03-16 2019-04-16 约翰霍普金斯大学 用于递送活性剂的非线性多嵌段共聚物-药物结合物
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
EP3808339A1 (fr) 2012-05-03 2021-04-21 Kala Pharmaceuticals, Inc. Nanoparticles pharmaceutiques montrant du transport mucosale amélioré
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
NZ742004A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9889208B2 (en) 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
JP2015529683A (ja) 2012-09-17 2015-10-08 バインド セラピューティックス インコーポレイテッド 治療剤を含む治療用ナノ粒子とその製造方法および使用方法
US20150265541A1 (en) 2012-09-20 2015-09-24 Akina, Inc. Biodegradable Microcapsules Containing Filling Material
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
JP6570513B2 (ja) 2013-04-01 2019-09-04 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続的眼内放出のためのマイクロスフェア薬剤送達システム

Also Published As

Publication number Publication date
AU2013256008A1 (en) 2014-11-20
WO2013166498A1 (fr) 2013-11-07
EP2849728A1 (fr) 2015-03-25
JP6392209B2 (ja) 2018-09-19
US9889208B2 (en) 2018-02-13
JP2018039836A (ja) 2018-03-15
JP2015515992A (ja) 2015-06-04
CA2872519A1 (fr) 2013-11-07
US20180169263A1 (en) 2018-06-21
US10556017B2 (en) 2020-02-11
AU2013256008B2 (en) 2016-02-25
US20150086484A1 (en) 2015-03-26
CA2872519C (fr) 2017-09-05

Similar Documents

Publication Publication Date Title
HK1208377A1 (en) Lipid-based drug carriers for rapid penetration through mucus linings
ZA201503280B (en) Physical channel design for network-assisted d2d
GB2518113B (en) Biofeedback system
HK1203517A1 (en) Multispecific antibodies
GB2501785B (en) Synchronisation method
IL236772A0 (en) Preparations for directed immunotherapy
EP2912432A4 (fr) Analyse cible à multiplexe intégré
GB201505407D0 (en) Methods for discovering therapeutic targets
EP2807890A4 (fr) Procédés d'analyse de couverture sur la liaison montante
GB201222970D0 (en) Synchronization
IL237879B (en) Video-assisted target location
GB2516389B (en) Refrigerating Apparatus
EP2824404A4 (fr) Réfrigérateur de médicaments
ZA201502685B (en) Capsules
EP2760035A4 (fr) Procédé de formation d'espace de champ magnétique
SG11201500859QA (en) Timer for releasing e-dch resources
PL2867530T3 (pl) Tłok
HK1201209A1 (en) Therapeutic agent for diabetes
IL238989B (en) A combined mediator/target for a neutron activation process
PL2861862T3 (pl) Popychacz
EP2917879A4 (fr) Outil de marquage
GB2502402B (en) Controlled drug release
EP2761958A4 (fr) Types de porteuse supplémentaire pour lte
EP2712550A4 (fr) Lancette
GB2500415B (en) Retort